Rep. Marjorie Taylor Greene Purchases Shares of AbbVie Inc. (NYSE:ABBV)

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on August 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on August 4th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/4/2025.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 8/4/2025.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 7/15/2025.
• Purchased $1,001 – $15,000 in shares of Palantir Technologies (NASDAQ:PLTR) on 7/15/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 6/17/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 6/17/2025.
• Sold $1,001 – $15,000 in shares of lululemon athletica (NASDAQ:LULU) on 6/17/2025.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 6/6/2025.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 6/6/2025.
• Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 6/6/2025.

AbbVie Trading Up 1.0%

Shares of NYSE:ABBV opened at $206.65 on Friday. The company has a 50-day simple moving average of $191.08 and a 200 day simple moving average of $192.20. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $365.06 billion, a P/E ratio of 98.41, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $218.66.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%. The company’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business earned $2.65 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were paid a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.2%. The ex-dividend date was Tuesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 312.38%.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently made changes to their positions in the stock. Teachers Insurance & Annuity Association of America bought a new stake in shares of AbbVie during the second quarter worth about $69,000. Evergreen Capital Management LLC grew its position in AbbVie by 1.4% in the 2nd quarter. Evergreen Capital Management LLC now owns 49,400 shares of the company’s stock worth $9,170,000 after purchasing an additional 703 shares in the last quarter. Headlands Technologies LLC grew its position in AbbVie by 234.0% in the 2nd quarter. Headlands Technologies LLC now owns 8,812 shares of the company’s stock worth $1,636,000 after purchasing an additional 6,174 shares in the last quarter. Nikulski Financial Inc. grew its position in AbbVie by 2.0% in the 2nd quarter. Nikulski Financial Inc. now owns 39,671 shares of the company’s stock worth $7,364,000 after purchasing an additional 775 shares in the last quarter. Finally, Security National Bank of Sioux City Iowa IA grew its position in AbbVie by 14.5% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 15,337 shares of the company’s stock worth $2,847,000 after purchasing an additional 1,948 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. Citigroup lifted their price target on shares of AbbVie to $205.00 and gave the company a “hold” rating in a research report on Wednesday, June 11th. Evercore ISI boosted their target price on shares of AbbVie from $204.00 to $205.00 and gave the stock an “outperform” rating in a research note on Monday, April 28th. BNP Paribas raised shares of AbbVie to a “hold” rating in a research note on Thursday, May 8th. Guggenheim boosted their target price on shares of AbbVie from $216.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price on the stock in a research note on Thursday, August 7th. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and five have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $214.95.

Insider Buying and Selling

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.